Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Clin Cancer Res. 2010 Jan 15;16(2):764-74. doi: 10.1158/1078-0432.CCR-09-2156. Epub 2010 Jan 12.
Although cigarette smoking and alcohol use are known risk factors for squamous cell carcinoma of head and neck (SCCHN), only a few exposed individuals develop this disease, suggesting an individual susceptibility. In this study, we investigated the associations between genetically determined DNA repair capacity (DRC) for removing tobacco-induced DNA adducts and risk of SCCHN and tumor characteristics.
We measured DRC in cultured T lymphocytes using the host-cell reactivation assay in a hospital-based case-control study of 744 SCCHN patients and 753 age-, sex-, and ethnicity-matched cancer-free controls recruited from The University of Texas M.D. Anderson Cancer Center.
Patients with SCCHN had significantly lower mean DRC (8.84% +/- 2.68%) than controls (9.97% +/- 2.61%; P < 0.0001), and the difference accounted for approximately 2-fold increased risk of SCCHN [adjusted odds ratio (OR), 1.91; 95% confidence interval (CI), 1.52-2.40] after adjustment for other covariates. Compared with the highest DRC quartile of controls, this increased risk was dose dependent (second highest quartile: OR, 1.40; 95% CI, 0.99-1.98; third quartile: OR, 1.87; 95% CI, 1.34-2.62; and fourth quartile: OR, 2.76; 95% CI, 1.98-3.84, respectively; P(trend) < 0.0001). We also assessed the performance of DRC in risk prediction models by calculating the area of under the receiver operating characteristic curve. The addition of DRC to the model significantly improved the sensitivity of the expanded model. However, we did not find the association between DRC and tumor sites and stages.
DRC is an independent susceptibility biomarker for SCCHN risk but not a tumor marker.
尽管吸烟和饮酒是头颈部鳞状细胞癌(SCCHN)的已知危险因素,但只有少数暴露个体患有这种疾病,这表明存在个体易感性。在这项研究中,我们研究了去除烟草诱导的 DNA 加合物的遗传决定的 DNA 修复能力(DRC)与 SCCHN 风险和肿瘤特征之间的关联。
我们使用基于医院的病例对照研究,在 744 例 SCCHN 患者和 753 名年龄、性别和种族匹配的无癌症对照中,使用宿主细胞复活测定法在培养的 T 淋巴细胞中测量 DRC。这些患者均来自德克萨斯大学 MD 安德森癌症中心。
与对照组(9.97% +/- 2.61%)相比,SCCHN 患者的平均 DRC(8.84% +/- 2.68%)显着降低(P <0.0001),差异约占 SCCHN 风险增加 2 倍[调整后的比值比(OR),1.91; 95%置信区间(CI),1.52-2.40],在调整其他协变量后。与对照组的最高 DRC 四分位组相比,这种风险增加是剂量依赖性的(第二高四分位组:OR,1.40; 95%CI,0.99-1.98;第三四分位组:OR,1.87; 95%CI,1.34-2.62;第四四分位组:OR,2.76; 95%CI,1.98-3.84; P(趋势)<0.0001)。我们还通过计算接收者操作特征曲线下的面积来评估 DRC 在风险预测模型中的性能。将 DRC 添加到模型中可显着提高扩展模型的灵敏度。然而,我们没有发现 DRC 与肿瘤部位和阶段之间的关联。
DRC 是 SCCHN 风险的独立易感性生物标志物,但不是肿瘤标志物。